Orion has been granted a patent for compounds that inhibit cytochrome P450 monooxygenase 11A1 (CYP11A1), potentially useful in treating androgen receptor-dependent conditions, including prostate cancer. The patent details various chemical structures and their pharmaceutical applications. GlobalData’s report on Orion gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Orion, Cancer treatment biomarkers was a key innovation area identified from patents. Orion's grant share as of July 2024 was 58%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12030871B2 encompasses a series of novel compounds characterized by specific chemical structures, primarily featuring a 4H-pyran-4-one core linked to various piperidine and isoindoline moieties. The claims detail multiple compounds, including those with different sulfonyl and acyl substituents, which may exhibit therapeutic potential. The patent also outlines methods for treating steroid receptor-dependent conditions, particularly focusing on androgen receptor-related diseases such as prostate cancer, including castration-resistant prostate cancer (CRPC). The compounds can be administered alone or in combination with glucocorticoids, mineralocorticoids, and various anti-cancer agents, enhancing their therapeutic efficacy.
Additionally, the patent specifies pharmaceutical compositions that incorporate these compounds along with acceptable carriers, emphasizing their potential for clinical application. The claims further extend to combinations of the novel compounds with a range of active ingredients, including non-steroidal androgen receptor antagonists, steroidogenesis inhibitors, and chemotherapeutic agents, among others. This comprehensive approach highlights the versatility of the compounds in addressing complex steroid receptor-dependent diseases, particularly in oncology, and suggests a pathway for developing effective treatment regimens for patients with advanced prostate cancer.
To know more about GlobalData’s detailed insights on Orion, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
